Kura Oncology (KURA) opened Q1 2026 with revenue of US$18.3 million and a basic EPS loss of US$0.83, while trailing 12 month figures show revenue of US$71.6 million and a basic EPS loss of US$3.35. Over recent quarters, the company has seen quarterly revenue move between US$14.1 million and US$20.8 million, with basic EPS losses in a range from US$0.66 to US$0.92. Investors are likely to weigh this latest print against expectations for faster top line growth relative to ongoing pressure on margins.

See our full analysis for Kura Oncology.

With the headline numbers on the table, the next step is to set these results against the prevailing market and community narratives to see which stories the latest margins support and which they challenge.

Losses Stay Heavy At Around US$73 Million

• Net income for Q1 2026 was a loss of US$73.3 million, with trailing 12 month losses at US$294.6 million, so the business is still spending much more than it brings in from revenue of US$18.3 million this quarter and US$71.6 million over the past year.
• Bears highlight that losses have widened at about 17.6% per year over the past five years and this quarter lines up with that concern, as:
  • Quarterly losses have sat in a band from US$57.4 million to US$81.0 million since early 2025, which fits the bearish view that rising R&D and other costs keep profitability out of reach.
  • Analysts who are cautious also expect Kura to remain unprofitable for at least the next three years, so the current trailing EPS loss of US$3.35 reinforces the idea that any future earnings recovery needs a big shift from where the numbers are today.

On this view, skeptics see Q1 as another period where heavy losses keep the focus on funding and execution risk rather than earnings progress, which is exactly the kind of setup they warn about when they point to Kura's long runway of spending before potential payoffs. 🐻 Kura Oncology Bear Case

Revenue At US$71.6 Million Trailing Yet Growth Expectations Stay Aggressive

• Across the last four reported quarters, Kura has booked US$71.6 million of revenue, with individual quarters moving between US$14.1 million and US$20.8 million, while forecasts referenced in the analysis point to roughly 40% annual revenue growth expectations even though actual quarterly figures are still in the tens of millions.
• The bullish narrative leans heavily on future product launches to turn this early revenue base into a much larger business, and the current run rate both supports and challenges that story in a few ways:
  • Support comes from the fact that there is already a meaningful revenue line, which bulls argue can scale rapidly if ziftomenib and other programs gain approval and adoption, matching the view that Kura could transition from early revenue to a much larger addressable market over time.
  • The tension is that trailing 12 month revenue of US$71.6 million is still far from the multi hundred million or billion dollar levels discussed in optimistic scenarios, so anyone leaning on that bullish case needs to recognise how much growth has to occur on top of the current base.

This mix of a modest current revenue base and very ambitious growth expectations is exactly what bullish investors point to as upside, while also being the gap more cautious investors watch closely. 🐂 Kura Oncology Bull Case

P/S Of 11.7x Prices In Growth While Losses Continue

• The stock trades on a trailing P/S of 11.7x compared with 9.7x for the broader US biotech industry and 12.7x for its closer peer group, so at a share price of US$9.48 the market is already paying somewhat more per dollar of sales than the sector average despite ongoing losses of US$294.6 million over the past year.
• Consensus narrative commentators point out that investors seem willing to pay this premium because of the expected revenue ramp, yet the current earnings profile introduces a clear trade off:
  • On one hand, revenue growth expectations of about 40% per year help explain why the P/S sits above the industry, suggesting some investors are comfortable valuing Kura more like a growth story than a mature profit maker.
  • On the other hand, analysts do not see Kura reaching profitability within the next three years, and the trailing EPS loss of US$3.35 shows that the premium multiple is being granted to a company where every additional dollar of revenue is still paired with sizable losses.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Kura Oncology on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Uncertain about whether this mix of heavy losses and ambitious growth expectations makes sense for your portfolio? Act while the data is fresh and test your own thesis by weighing both sides with our breakdown of 1 key reward and 1 important warning sign

See What Else Is Out There

Kura Oncology is still posting sizable annual losses of about US$294.6 million on a relatively modest revenue base and is not expected to reach profitability soon.

If you want less balance sheet stress and a clearer path to stability, use the 68 resilient stocks with low risk scores to quickly spot companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.